Meeting
2016 ASCO Annual Meeting
Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.
Authors
Jonathan Foote
Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
Jonathan Foote , Margaret Liang , Angeles Alvarez Secord , David E. Cohn , Laura Jean Havrilesky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6630)
DOI
10.1200/JCO.2016.34.15_suppl.6630
Abstract #
6630
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?
First Author: Jonathan Foote
Poster
2017 ASCO Annual Meeting
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2016 ASCO Annual Meeting
A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth line treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2015 ASCO Annual Meeting
A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
First Author: Frédéric Selle